AIHTA - Publications - Search - Person: Rothschedl, E.
Number of items: 26.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 35th Prioritisation – 2nd quarter 2018. HSO: 35th Prioritisation.

Rothschedl, E. and Nachtnebel, A. (2013): Aflibercept (Zaltrap®) in addition to FOLFIRI for the 2nd line therapy of metastatic colorectal cancer. DSD: Horizon Scanning in Oncology 38.

Rothschedl, E. and Nachtnebel, A. (2015): Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with bevacizumab plus chemotherapy. DSD: Horizon Scanning in Oncology 51.

Rothschedl, E. and Nachtnebel, A. (2013): Regorafenib (Stivarga®) for heavily pretreated patients with metastatic colorectal cancer (mCRC). DSD: Horizon Scanning in Oncology 40.

Rothschedl, E. (2019): Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC). DSD: Horizon Scanning in Oncology 90.

Rothschedl, E. and Nachtnebel, A. (2015): Defibrotide for the treatment and prophylaxis of hepatic veno-occlusive disease. Decision Support Document 84.

Groessmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 39th Prioritisation – 2nd quarter 2019 . HSO: 39th Prioritisation.

Rothschedl, E. (2018): Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 84.

Rothschedl, E. and Joppi, R. and Poggiani, C. (2014): Idelalisib (Zydelig®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 49.

Rothschedl, E. (2018): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC. DSD: Horizon Scanning in Oncology 82.

Rothschedl, E. (2019): Olaparib (Lynparza®) as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer. DSD: Horizon Scanning in Oncology 86.

Grössmann, N. and Wolf, S. and Rothschedl, E. (2019): Horizon Scanning in Oncology 38th Prioritisation – 1st quarter 2019. HSO: 38th Prioritisation.

Rothschedl, E. and Nachtnebel, A. (2016): Bevacizumab (Avastin®) in addition to standard chemotherapy for the first-line treatment of ovarian cancer. DSD: Horizon Scanning in Oncology 56.

Rothschedl, E. (2019): Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 88.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 41st Prioritisation – 4th quarter 2019. HSO: 41st Prioritisation.

Rothschedl, E. and Nachtnebel, A. (2015): Horizon Scanning in Oncology: Results of the 22nd Prioritisation – 1st quarter 2015. HSO: 22nd Prioritisation.

Rothschedl, E. and Nachtnebel, A. (2015): Horizon Scanning in Oncology: Results of the 24th Prioritisation – 3rd quarter 2015. HSO: 24th Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 37th Prioritization – 4th quarter 2018. HSO: 37th Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 40th Prioritisation – 3rd quarter 2019. HSO: 40th Prioritisation.

Rothschedl, E. and Nachtnebel, A. (2015): Pembrolizumab (Keytruda®) for the treatment of advanced melanoma. DSD: Horizon Scanning in Oncology 55.

Rothschedl, E. (2018): Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL). DSD: Horizon Scanning in Oncology 79.

Rothschedl, E. and Nachtnebel, A. (2014): Bevacizumab (Avastin®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal carcinoma. DSD: Horizon Scanning in Oncology 46.

Rothschedl, E. and Nachtnebel, A. (2015): Horizon Scanning in Oncology 23rd Prioritisation – 2nd quarter 2015. HSO: 23rd Prioritisation.

Zechmeister-Koss, I. and Rothschedl, E. (2015): Fully bioresorbable scaffolds for coronary artery disease. Decision Support Document 81.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 36th Prioritisation – 3rd quarter 2018. HSO: 36th Prioritisation.

Rothschedl, E. (2018): Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma. DSD: Horizon Scanning in Oncology 81.

This list was generated on Sat Apr 25 15:01:51 2020 CEST.